A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma.
5-Fluorouracil (5-FU) was delivered in a dose-intensive schedule to 23 patients with metastatic or unresectable colorectal carcinoma. The schedule consisted of bolus single-dose 5-FU therapy 400 to 500 mg followed by 4-day infusion of 5-FU, 600 to 800 mg/m2/day, followed by a 17-day to 24-day infusion of 200 to 250 mg/m2/day. Partial remissions were seen in 22% of all eligible patients. Significant toxicity, including mucositis, diarrhea, and hand-foot syndrome, necessitated dose reductions in most patients. The authors conclude that 5-FU given in this moderately intensive schedule is associated with a moderate level of response, as easily achieved with more conventional schedules or with 5-FU-leucovorin combinations. Tumor responsiveness to dose intensive 5-FU regimens may be limited.
Poplin
E A
EA
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan.
Kraut
M
M
Baker
L
L
Brodfuehrer
J
J
Vaitkevicius
V
V
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010386:Pelvic Neoplasms / Q000188:drug therapy / Q000556:secondary; D012074:Remission Induction; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000556:secondary
D005472:Fluorouracil